<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">15991152</PMID>
      <DateCompleted>
        <Year>2005</Year>
        <Month>09</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0033-0620</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>47</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2005</Year>
              <Season>Jan-Feb</Season>
            </PubDate>
          </JournalIssue>
          <Title>Progress in cardiovascular diseases</Title>
          <ISOAbbreviation>Prog Cardiovasc Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Chlamydia pneumoniae and atherosclerosis: from Koch postulates to clinical trials.</ArticleTitle>
        <Pagination>
          <StartPage>230</StartPage>
          <EndPage>239</EndPage>
          <MedlinePgn>230-9</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Atherosclerosis is increasingly viewed as an inflammatory process. A number of infectious agents have been implicated in the pathogenesis of coronary artery disease. Chlamydia pneumoniae has been the most popular and well-studied of these pathogens. It is difficult to prove a causal relationship which requires the fulfillment of Koch's postulates, first developed in the late 1800s, to establish an infectious agent as the cause of a disease process. This paper reviews the evidence for and against Chlamydia pneumoniae infection as a contributing factor to atherosclerosis disease. It examines seroepidemiologic and histopathologic studies as well as animal models using Koch's postulates and then provides an analysis of current clinical trial data.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Catherine</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Cardiology, Department of Medicine, San Francisco General Hospital, University of California, 94110, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Waters</LastName>
            <ForeName>David D</ForeName>
            <Initials>DD</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Prog Cardiovasc Dis</MedlineTA>
        <NlmUniqueID>0376442</NlmUniqueID>
        <ISSNLinking>0033-0620</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001161" MajorTopicYN="N">Arteriosclerosis</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023521" MajorTopicYN="N">Chlamydophila Infections</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016993" MajorTopicYN="Y">Chlamydophila pneumoniae</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2005</Year>
          <Month>7</Month>
          <Day>2</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2005</Year>
          <Month>9</Month>
          <Day>3</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2005</Year>
          <Month>7</Month>
          <Day>2</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">15991152</ArticleId>
        <ArticleId IdType="pmc">PMC7118749</ArticleId>
        <ArticleId IdType="doi">10.1016/j.pcad.2005.01.001</ArticleId>
        <ArticleId IdType="pii">S0033062005000034</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Frothingham C. The relation between acute infectious diseases and arterial lesions. Arch Intern Med. 1911;8:153–162.</Citation>
        </Reference>
        <Reference>
          <Citation>Minick C.R., Fabricant C.G., Fabricant J. Atheroarteriosclerosis induced by infection with a herpesvirus. Am J Pathol. 1979;96:673–706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2042405</ArticleId>
            <ArticleId IdType="pubmed">382868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grattan M.T., Moreno-Cabral C.E., Starnes V.A. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 1989;261:3561–3566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2542633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grattan M.T. Accelerated graft atherosclerosis following cardiac transplantation: Clinical perspectives. Clin Cardiol. 1991;14:16–20.</Citation>
        </Reference>
        <Reference>
          <Citation>McDonald K.M., Rector T.S., Braunlin E.A. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol. 1989;64:359–362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2547298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y.F., Leon M.B., Waclawiw M.A. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med. 1996;335:624–630.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8687516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorlie P.D., Nieto F.J., Adam E. A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2000;160:2027–2032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10888976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ridker P.M., Hennekens C.H., Stampfer M.J. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation. 1998;98:2796–2799.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9860778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siscovick D.S., Schwartz S.M., Corey L. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus, and incident myocardial infarction and coronary heart disease death in older adults: The cardiovascular health study. Circulation. 2000;102:2335–2340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11067785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danesh J., Collins R., Peto R. Chronic infections and coronary heart disease: Is there a link? Lancet. 1997;350:430–436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9259669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasceri V., Cammarota G., Patti G. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation. 1998;97:1675–1679.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9591760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Espinola-Klein C., Rupprecht H.J., Blankenberg S. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation. 2002;105:15–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11772870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rupprecht H.J., Blankenberg S., Bickel C. Impact of viral and bacterial infectious burden on long-term prognosis of patients with coronary artery disease. Circulation. 2001;104:25–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11435333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiechl S., Egger G., Mayr M. Chronic infections and the risk of carotid atherosclerosis: Prospective results from a large population study. Circulation. 2001;103:1064–1070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11222467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuo C.C., Jackson L.A., Campbell L.A. Chlamydia pneumoniae. Clin Microbiol Rev. 1995;8:451–461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC172870</ArticleId>
            <ArticleId IdType="pubmed">8665464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campbell L.A., Kuo C.C., Grayston J.T. Chlamydia pneumoniae and cardiovascular disease. Emerg Infect Dis. 1998;4:571–579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2640250</ArticleId>
            <ArticleId IdType="pubmed">9866733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saikku P., Leinonen M., Mattila K. Serologic evidence for an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983–986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2902492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saikku P., Leinonen M., Tenkanen L. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992;116:273–278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1733381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huittinen T., Leinonen M., Tenkanen L. Synergistic effect of persistent Chlamydia pneumoniae infection, autoimmunity, and inflammation on coronary risk. Circulation. 2003;107:2566–2570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12743003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boman J., Hammerschlag M.R. Chlamydia pneumoniae and atherosclerosis: Critical assessment of diagnostic methods and relevance to treatment studies. Clin Microbiol Rev. 2002;15:1–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC118057</ArticleId>
            <ArticleId IdType="pubmed">11781264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kutlin A., Roblin P.M., Hammerschlag M.R. Antibody response to Chlamydia pneumoniae infection in children with respiratory illness. J Infect Dis. 1998;177:720–724.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9498453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hyman C.L., Roblin P.M., Gaydos C.A. Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: Assessment by polymerase chain reaction–enzyme immunoassay and culture. Clin Infect Dis. 1995;20:1174–1178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7619996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danesh J., Whincup P., Walker M. Chlamydia pneumoniae IgG titres and coronary heart disease: Prospective study and meta-analysis. BMJ. 2000;321:208–213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC27437</ArticleId>
            <ArticleId IdType="pubmed">10903653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bloemenkamp D.G., Mali W.P., Visseren F.L. Meta-analysis of sero-epidemiologic studies of the relation between Chlamydia pneumoniae and atherosclerosis: Does design influence results? Am Heart J. 2003;145:409–417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12660662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shor A., Kuo C.C., Patton D.L. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J. 1992;82:158–161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1519134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibbs R.G., Carey N., Davies A.H. Chlamydia pneumoniae and vascular disease. Br J Surg. 1998;85:1191–1197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9752857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramirez J.A. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med. 1996;125:979–982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8967709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maas M., Bartels C., Engel P.M. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol. 1998;31:827–832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9525555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss S.M., Roblin P.M., Gaydos C.A. Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis. 1996;173:957–962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8603977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fong I.W., Chiu B., Viira E. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol. 1997;35:48–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC229510</ArticleId>
            <ArticleId IdType="pubmed">8968879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laitinen K., Laurila A., Pyhala L. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun. 1997;65:4832–4835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC175693</ArticleId>
            <ArticleId IdType="pubmed">9353072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moazed T.C., Campbell L.A., Rosenfeld M.E. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E–deficient mice. J Infect Dis. 1999;180:238–241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10353889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muhlstein J.B., Anderson J.L., Hammond E.H. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998;97:633–636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9495296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dosquet C., Weill D., Wautier J.L. Cytokines and thrombosis. J Cardiovasc Pharmacol. 1995;25:13–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8699851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakayama K., Masuno H., Okumura H. Recombinant human tumor necrosis factor-alpha suppresses synthesis, activity, and secretion of lipoprotein lipase in cultures of human osteosarcoma cell line. Biochem J. 1996;316:813–817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1217422</ArticleId>
            <ArticleId IdType="pubmed">8670156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Libby P., Egan D., Skarlatos S. Role of infectious agents in atherosclerosis and restenosis: An assessment of the evidence and need for future research. Circulation. 1997;96:4095–4103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9403635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kol A., Sukhova G.K., Lichtman A.H. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation. 1998;98:300–307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9711934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta S., Leatham E.W., Carrington D. Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404–407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9244203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gurfinkel E., Bozovich G., Beck E. Treatment with the antibiotic roxithromycin in patients with acute non–Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J. 1999;20:121–127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10099908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muhlstein J.B., Anderson J.L., Carlquist J.F. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: Preliminary clinical results of the ACADEMIC study. Circulation. 2000;102:1755–1760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11023928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinisalo J., Mattila K., Valtonen V. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non–Q-wave coronary syndrome. Circulation. 2002;105:1555–1560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11927522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Connor C., Dunne M.W., Pfeffer M.A. Azithromycin for the secondary prevention of coronary heart disease events. The WIZARD study: A randomized controlled trial. JAMA. 2003;290:1459–1466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13129985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brassard P., Bourgault C., Brophy J. Antibiotics in primary prevention of myocardial infarction in elderly patients with hypertension. Am Heart J. 2003;145:E20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12766754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neumann F., Kastrati A., Miethke T. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointimal proliferation after coronary stent placement (ISAR-3): A randomized, double-blind, placebo-controlled trial. Lancet. 2001;357:2085–2089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11445102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ngeh J., Anand V., Gupta S. Chlamydia pneumoniae and atherosclerosis—what we know and what we don't. Clin Microbiol Infect. 2002;8:2–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11906495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gelfand E.V., Cannon C.P. Antibiotics for secondary prevention of coronary artery disease: An ACES hypothesis but we need to PROVE IT. Am Heart J. 2004;147:202–209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14760314</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
